Evergreen Therapeutics, Inc.

This early-stage study tests a new drug called EG-101 in 24 healthy women to check its safety before giving it to pregnant women with severe pre-eclampsia, a dangerous condition that causes high blood pressure and organ damage. The study measures how the drug moves through the bo…

This phase 3 trial tests whether adding the drug EG007 to a standard two-drug therapy (lenvatinib plus pembrolizumab) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 adults whose cancer has returned after platinum che…